Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$9.54 USD
+0.07 (0.74%)
Updated Apr 25, 2024 03:59 PM ET
4-Sell of 5 4
B Value F Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ALPMY 9.54 +0.07(0.74%)
Will ALPMY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALPMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALPMY
New Strong Sell Stocks for October 2nd
New Strong Sell Stocks for September 26th
ALPMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for September18th
New Strong Sell Stocks for August 21st
ALPMY or ZTS: Which Is the Better Value Stock Right Now?
Other News for ALPMY
Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidance
Warning: ALPMY is at high risk of performing badly
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Takeda, Astellas and Sumitomo to create new drug discovery company
Takeda, Astellas Pharma and Sumitomo Mitsui to establish joint venture company